Renal Cancer Clinical Trials

Denver : The Urology Center of Colorado

Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma.

Baltimore : University of Maryland Greenebaum Cancer Center

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

Boston : Beth Israel Deaconess Medical Center

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

Hackensack : Hackensack University Medical Center

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

New York : Memorial Sloan Kettering Cancer Center

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

New York : Memorial Sloan-Kettering Cancer Center

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Durham : Duke University Medical Center

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

Charleston : Medical University of South Carolina Hollings Cancer Center

Study of Panobinostat in Combination With Sorafenib in Kidney or Lung Cancers

San Antonio : South Texas Accelerated Research Therapeutics (START)

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma